Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 7,882 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non intervention study Clear all

Conditions: ESRD
Interventions: Hispanic Kidney Transplant Program (HKTP); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11,836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Phoenix, Arizona • Denver, Colorado • Dallas, Texas + 1 more

Conditions: Opioid Use
Interventions: Not applicable- observational study; Other
Lead sponsor: Tenvos Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Malignant Non-small Cell Neoplasm of Lung Stage IV
Interventions: Capmatinib (INC280); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Elevated Blood Pressure
Interventions: Vascanox® HP; Dietary Supplement
Lead sponsor: Calroy Health Sciences; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Brain Cancer, Brain Stem Glioma
Interventions: Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Atrial Fibrillation, Arrhythmias, Cardiac
Interventions: Standard Atrial fibrillation ablation, Coronary sinus to left atrium connection elimination; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adolescent Vaccination Status
Interventions: Email Notification; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 3,783 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Type 2
Interventions: Human Regular U-500 Insulin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 35
States / cities: Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more

Conditions: Obesity, Adolescent
Interventions: Commercial Advertising Literacy Training, Control; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Obesity, Metabolic Syndrome
Interventions: Metabolic flexibility in the fasted state, Metabolic flexibility in euglycemic-hyperinsulinemic clamp, Metabolic flexibility in the metabolic chamber; Diagnostic Test · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions: cyclophosphamide, fludarabine phosphate, vincristine sulfate, prednisone, rituximab, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Children With Medical Complexity
Interventions: MyChildCMC app; Other
Lead sponsor: University of Utah; Other
Eligibility: 1 Year to 20 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes
Interventions: Intervention for age specific barriers to self care; Other
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 69 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Taletrectinib, Placebo; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Fludarabine, CAR-T Cells; Drug · Biological
Lead sponsor: Benjamin Tomlinson; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 2
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Vestibulocochlear Nerve Diseases, Vestibular Disorder, Bilateral Vestibular Loss
Interventions: Vestibular Balance Therapy, Sham Intervention; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 4 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cancer
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Columbus, Ohio • Nashville, Tennessee

Conditions: Autistic Disorder
Interventions: Vitamin D3; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 20 Years to 44 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Oregon City, Oregon

Conditions: Cancer, Pain, Advanced Cancer
Interventions: Cancer Pain 101; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Arthritis, Rheumatoid
Interventions: Silicone metacarpophalangeal joint arthroplasty, Usual care; Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Wound Complications, Wound Infection, Wound Separation
Interventions: Prospective wound complication protocol; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more

Conditions: Melanoma
Interventions: Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration; Other · Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cardiovascular Diseases, Breast Cancer, Prostate Cancer, Physical Inactivity
Interventions: Gamification and Social Support, Attention control; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Duarte, California • Philadelphia, Pennsylvania

Search by objective public record fields.

A Culturally Targeted Transplant Program

Voice Technology to Identify Opioid Use

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial

Adolescent Vaccination Reminder Study

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Promoting Resilience to Food Commercials Decreases Susceptibility to Unhealthy Food Decision-Making

Impact of Metabolic Flexibility on Changes in Metabolic Health

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Self-management Intervention for Children With Chronic Medical Complexity: Pilot Feasibility Trial

Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Vestibular Balance Therapy Intervention for Children

Met Non Small Cell Cancer Registry (MOMENT)

Vitamin D to Prevent Autism in Newborn Siblings

Cancer Pain 101: A Digital, Asynchronous Intervention of Pain Management in Advanced Cancer

Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand

A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)